Brett Kaplan Net Worth

Brett Kaplan biography

Dr. Brett I. Kaplan M.D. serves as Chief Financial Officer of the Company. From August 2010 to November 2018, he worked at Evercore, an investment bank, where he most recently served as Managing Director with a focus on mergers and acquisitions and equity financings in the biopharmaceutical industry. Prior to Evercore, Dr. Kaplan was an Equity Research Analyst at Cowen and Company, an investment bank, from 2007 to 2010. Previously, Dr. Kaplan served as Director of Corporate Development at Cubist Pharmaceuticals, a pharmaceutical company acquired by Merck & Co., Inc., or Merck, in 2014, Manager of Strategic Medical Marketing at Biopure Corporation, and Manager of Corporate Development and Strategy at Eli Lilly and Company. Dr. Kaplan received an M.B.B.Ch. and an M.B.A. from the University of Witwatersrand.

How old is Brett Kaplan?

Brett Kaplan is 46, he's been the Chief Financial Officer of Prevail Therapeutics Inc since 2018. There are 11 older and 1 younger executives at Prevail Therapeutics Inc. The oldest executive at Prevail Therapeutics Inc is Franz Hefti, 72, who is the Chief Development Officer.

What's Brett Kaplan's mailing address?

Brett's mailing address filed with the SEC is C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK, NY, 10016.

Insiders trading at Prevail Therapeutics Inc

Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson und Advisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.

What does Prevail Therapeutics Inc do?

Prevail Therapeutics Inc executives and stock owners

Prevail Therapeutics Inc executives and other stock owners filed with the SEC include:

• Asa Abeliovich,
  President, Chief Executive Officer, Director
• Jeffrey Sevigny,
  Chief Medical Officer
• Yong Dai,
  Chief Technology Officer
• Franz Hefti,
  Chief Development Officer
• Francois Nader,
  Independent Chairman of the Board
• Timothy Adams,
  Independent Director
• Morgan Sheng,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Carl Gordon,
  Director
• Peter Thompson,
  Independent Director
• William Carson,
  Director
• Emily Minkow,
  Chief Business Officer
• Kira Schwartz,
  General Counsel
• Brett Kaplan,
  Chief Financial Officer
• Advisors Llc Orbi Med Capit...,
  
• Acquisition Corp Eli Lilly ...,